Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

被引：0
|
作者：
Carulla, Yannick
Neidhardt, Eve-Marie
Karabajakian, Andy
Gauduchon, Thibault
Guevara, Hemerson
Roux, Pierre Eric
Zrounba, Philippe
Podeur, Fabien
Poupart, Marc
Excoffier, Aude
Fayette, Jerome
机构：
[1] Ctr Leon Berard, Lyon, France
[2] 28 Promenade Lea & Napoleon Bullukian, Lyon, France
[3] Owkin France, Paris, France
[4] Ctr Leon Berad, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18027
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Role of STAT3 (signal transducer and activator of transcription 3) activation and its regulation by PTPRT (protein receptor tyrosine phosphatase type T) and response to paclitaxel and cetuximab in patients (P) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Cirauqui Cirauqui, B.
    Bernat Peguera, A.
    Quer Pi-Sunyer, A.
    Ramirez Serrano, J. L.
    Domenech Vinolas, M.
    Teruel Garcia, I.
    Quiroga Garcia, V.
    Margeli Vila, M.
    Chaib, I.
    Capdevila Riera, L.
    Ferrando Diez, A.
    Plaja Salarich, A.
    Angelats Company, L.
    Espana Fernandez, S.
    Berenguer Peinado, G.
    Lezcano Rubio, C.
    Pollan Guisasola, C.
    Martinez Cardus, A.
    Rosell Costa, R.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S681 - S681
  • [42] Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]
    Pennel, Elicia
    Kapp, Amy V.
    Do, An
    Tam, Rachel
    Sumiyoshi, Teiko
    Marathe, Chaitra
    Sa, Susan
    Peale, Franklin
    Lackner, Mark
    Holden, Scott
    Seiwert, Tanguy
    Pirzkall, Andrea
    CANCER RESEARCH, 2015, 75
  • [43] Response to salvage chemotherapy with paclitaxel plus /cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
    Gomez, R. G. Herrera
    Saleh, K.
    Auclin, E.
    Vinches, M.
    Gervais, C.
    Espeli, V. G.
    Rothschild, S. I.
    Even, C.
    Cristina, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [44] Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019.
    Saba, Nabil F.
    Shukla, Soham
    Aguilar, Kathleen M.
    Ballas, Marc S.
    Bell, Kelly
    Boyd, Marley
    Chao, Jessica
    Ellis, Catherine Elizabeth
    Phiri, Kelesitse
    Tseng, Wan-Yu
    Nadler, Eric S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.
    Mehra, Ranee
    Seiwert, Tanguy Y.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Meister, Amy
    Hille, Darcy
    Cheng, Jonathan D.
    Chow, Laura Quan Man
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase Ill trial.
    Guo, Ye
    Ahn, Myung-Ju
    Chan, Anthony T. C.
    Wang, Cheng-Hsu
    Kang, Jin Hyoung
    Kim, Sung-Bae
    Bello, Maximino De Guzman
    Arora, Rajendra Singh
    Zhang, Qingyuan
    He, Xiaohui
    Li, Ping
    Dechaphunkul, Arunee
    Kumar, Vijay
    Kamble, Krishna
    Li, Wei
    Kandil, Alaa
    Cohen, Ezra E. W.
    Geng, Yuan
    Zografos, Lef
    Tang, Ping Zhang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Petosemtamab compared with investigator's choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
    Haddad, R.
    Gillison, M.
    Harrington, K. J.
    Kim, S-B.
    Le Tourneau, C.
    Rosenberg, A.
    Ford, J.
    Shen, Y-M.
    Yao, D.
    Zohren, F.
    Machiels, J-P.
    ANNALS OF ONCOLOGY, 2024, 35 : S653 - S654
  • [48] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
    Fayette, J.
    Licitra, L. F. L.
    Harrington, K. J.
    Haddad, R.
    Siu, L. L.
    Liu, Y. C.
    Tahara, M.
    Machiels, J-P.
    Rischin, D.
    Seiwert, T.
    Ferris, R.
    Keilholz, U.
    Psyrri, A.
    Keam, B.
    Bossi, P.
    Metcalf, R.
    Serrano, O.
    Kaur, P.
    Ruscica, D.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2023, 34 : S554 - S555
  • [50] Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
    Pontes, F.
    Rego, I.
    Domingues, I. C.
    Pinto, L.
    Garcia, R.
    Teixeira, M. M.
    Serra, T.
    Khoury, L.
    Mariano, M.
    Sousa, G. M.
    ANNALS OF ONCOLOGY, 2019, 30
12345